Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations

NCT05050149 is registered in ClinicalTrials.gov with Palvella Therapeutics, Inc. as lead sponsor.

NCT NCT05050149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations
Lead sponsor
Palvella Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 13, 2022
Completion date
December 15, 2022
Enrollment
12 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

microcystic lymphatic malformation